Thus, the spike in IL-1 observed here in vitro may still be of relevance in vivo and thus, may still have a considerable impact upon the efficacy of Bortezomib, and potentially any other proteasome inhibitors, as anti-cancer treatments. The gene discussed is IL1B; the disease is cancer.